PloS one
Cure8 research brief
Why This Matters
People taking isotretinoin may face a range of reported adverse events, including psychiatric and gastrointestinal issues and pregnancy-related risks. The study highlights signals (including IBD) that could affect monitoring and counseling practices.
Who Should Pay Attention
Adults prescribed isotretinoin; dermatologists and prescribers; clinicians monitoring gastrointestinal or psychiatric symptoms; pharmacovigilance researchers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper systematically analyzed 20 years of adverse-event reports for isotretinoin from FAERS with external validation in the European EudraVigilance database.
The authors used multiple disproportionality methods and identified 469 robust statistical signals across many organ systems, with prominent clusters in psychiatric, gastrointestinal, and pregnancy-related events.
Inflammatory bowel disease appeared as one of the strongest signals, but the authors note temporal clustering and reporter profiles that suggest stimulated reporting (for example litigation) may inflate that signal.
The study also surfaced several higher-ranking signals not clearly listed on current product labels (examples named by the authors include nasal vestibulitis, hypertrophic anal papilla, and SAPHO syndrome). The authors emphasize that spontaneous-reporting signals do not establish causation and that clinical relevance needs further study.
They recommend strengthened clinical monitoring and rigorous pregnancy prevention strategies for isotretinoin users.
Keep In Mind
Findings are from disproportionality analyses of spontaneous-reporting databases (FAERS and EudraVigilance) and indicate statistical signals, not proven causal effects. The abstract notes possible stimulated reporting (e.g., litigation) affecting some signals. Full-text review is recommended for clinical decision-making.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPloS one
AuthorsQian Chen, JinYue Li, Mao Zhang +4 more
InstitutionDepartment of Pharmacy, Affiliated Hospital of Southwest Medical University, Luzhou city, Sichuan Province, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: The authors have declared that no competing interests exist.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Adverse Events Associated with Advanced Therapy Compared with Conventional Therapy in Patients with Inflammatory Bowel Disease: A Common Data Model Analysis.
The study highlights higher risks of tuberculosis and depression/anxiety associated with advanced therapies—especially anti-TNF agents—which are relevant safety concerns for people with IBD and their care teams. It may...
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...